Abstract:Abstract Introduction Antiresorptive therapy (ArT) has been known to decrease the risk of skeletal-related events (SRE), such as bone pain and pathological fractures, in cancer patients with bone metastasis (BM). While beneficial, ArT may cause adverse effects in this population including hypocalcemia, which can be severe and life-threatening. We examined the incidence, severity, and risk factors for hypocalcemia associated with the use of ArT to treat BM in cancer patients. Methods We conducted a retrospective review of the electronic medical records of adult patients with advanced cancer complicated by BM who were treated at our institution between January 2016 and November 2020. Our primary aim was to compare the incidence and severity of hypocalcemia with the use of IV Zoledronic acid (ZA), a bisphosphonate, vs SQ Denosumab (DM), a RANKL inhibitor, to treat BM in cancer patients.Our secondary aim was to compare risk factors associated with severe hypocalcemia (defined as albumin-corrected serum calcium < 7 mg/dL). Inclusion criteria were patients aged 19-99 years with a history of cancer with known BM, who received either ZA or DM. Results We reviewed 860 EMRs of patients treated within the specified period. 392 patients met inclusion criteria, among them, 297 (76%) and 95 (24%) received DM and ZA, respectively. There were no between-group differences in age, ethnicity, or weight. The median patient age was 71 years (range: 27–96). There were, however, between-group differences in gender (p=0.01) and cancer diagnoses (p=0.03). Females comprised 53.9% of the DM group vs. 40% of the ZA group. The top three cancer diagnoses were (DM vs ZA groups): breast (40.1% vs 26.3%), prostate (25.9% vs 40%), and lung cancer (17.8% vs 15.8%). Overall incidence of hypocalcemia was 48.8% (n=144) and 45.3% (n= 43) with the use of DM and ZA, respectively (p=NS). Severe hypocalcemia was more frequently observed with the use of DM vs ZA (6.6% vs 1.1%, p <0.05). Median (IQR) corrected serum calcium concentration following ArT (when trending calcium for the individual patient) was 8.4 (7.9-8.8) and 8.6 (8.2-8.8) mg/dL for DM a ZA groups, respectively (p=0.1). There were no between-group differences in risk factors for hypocalcemia, such as renal function (eGFR), concentrations of 25-hydroxy vitamin D, albumin, phosphorus, magnesium, or TSH. However, there was a between-group difference in the concentration of alkaline phosphatase (median 83 vs 101 IU/L for DM vs ZA, p= 0.02). There were no between-group differences in the type of BM (osteolytic vs osteoblastic, p=0.9) Conclusion: Severe hypocalcemia was significantly more common with the use of DM compared to ZA for the treatment of BM in cancer patients treated at our institution. Our study was limited by its retrospective design and the between-group differences in gender distribution and cancer diagnoses. Presentation: Saturday, June 11, 2022 1:00 p.m. - 3:00 p.m.

Hypocalcemia Event Associated with Denosumab: A Real-World Study from FDA Adverse Event Reporting System (FAERS) Database

Efficacy and Safety of Denosumab in Postmenopausal Women with Osteoporosis

Hypocalcemia in Patients With Osteoporosis and Normal Renal Function, Treated With Denosumab, a Retrospective Analysis

Incidence of Hypocalcemia in Patients with Post-Menopausal Osteoporosis or Cancer Skeletal Related Events after Denosumab in Comparison to Zoledronic Acid in a Community Hospital Setting

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab

Denosumab-induced hypocalcemia in patients with solid tumors and renal dysfunction: a multicenter, retrospective, observational study

Analysis of adverse drug reactions of Denosumab (Prolia) in osteoporosis based on FDA adverse event reporting system (FAERS)

Denosumab and risk of hypocalcaemia ... and other research

Hypocalcemia and Hypophosphatemia following Concurrent Denosumab Injection and Ferric Carboxymaltose Infusion in a Patient with Normal Renal Function

Safety of denosumab versus zoledronic acid in the older adults with osteoporosis: a meta-analysis of cohort studies

Adverse events associated with teriparatide: a real-world disproportionality analysis of the FDA adverse event reporting system (FAERS)

Denosumab-associated symptomatic hypophosphatemia in normal kidney function: two case reports

Post-craniopharyngioma surgery hypocalcemia due to denosumab use for osteoporosis: A case report

PSAT164 Incidence and Severity of Hypocalcemia in Association with Antiresorptive Therapy in Cancer Patients with Bone Metastasis: An Integrated Health Network Experience

Atypical femoral fracture in a patient treated with denosumab

Safety of In-hospital Parenteral Antiosteoporosis Therapy Following a Hip Fracture: A Retrospective Cohort

Real-world Data of Efficacy and Safety of Denosumab on Patients with Breast Cancer with Bone Metastasis: Results from Chinese Clinical Experience.

Dose-specific effects of denosumab on serum calcium levels in patients with osteoporosis and various renal functions

Neuropsychiatric adverse reactions in patients treated with denosumab: two case reports and a review of data from the FDA Adverse Event Reporting System (FAERS)

The relationship between chronic kidney disease and denosumab-induced hypocalcemia in high-age osteoporotic patients

Comparison of Clinical Efficacy and Safety Between Denosumab and Alendronate in Postmenopausal Women with Osteoporosis: a Meta-Analysis